Supernus Pharmaceuticals, Inc. (SUPN): Market Value

The market valuation visualization for Supernus Pharmaceuticals (SUPN) shows a capitalization of 3.71. Business stability in the US is guaranteed by patent protection and an absence of political risks. Supernus Pharmaceuticals (SUPN) focuses on ethical R&D to combat psychiatric disorders, attracting leading neurobiologists. Primary revenue is generated through the supply of specialized drugs to insurance funds for the therapy of ADHD and epilepsy.

SUPN Supernus: Market Capitalization in the range 07/04/2022 - 11/15/2026

SUPN (Supernus): analytical breakdowns and indicator data

- stock price and consensus target price:

Stock Quotes Supernus Pharmaceuticals, Inc.|SUPN - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Supernus|SUPN - Full Business Value

- book value of equity indicators:

Net Assets per Single Share Supernus|SUPN - Accounting Capitalization|Market Value to Book Value Ratio supernus.com|SUPN - Total Business Assets

- debt burden and liquidity indicators:

Total Debt to Capital Supernus Pharmaceuticals|SUPN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio supernus.com|SUPN - Company Aggregate Debts|Debt to Book Capitalization Ratio Supernus Pharmaceuticals, Inc.|SUPN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Supernus|Quick Liquidity supernus.com

- business earnings and investment ratios data:

SUPN - Net Financial Result|Future Profit Supernus Pharmaceuticals|SUPN - P/E Multiple|Future Price to Earnings Supernus Pharma|SUPN - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Supernus Corp|SUPN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Supernus|SUPN - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months supernus.com|SUPN - Earnings per share growth this year|Expected earnings per share growth for next year Supernus Pharmaceuticals

- sales and revenue indicators:

SUPN - Revenue and Sales Volume|Company Projected Revenue Supernus Corp|SUPN - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc.

Fundamental company analysis:SUPN (Supernus Pharma)

Patent protection for CNS drugs provides Supernus Pharmaceuticals (SUPN) with significant pricing power, directly impacting the investment attractiveness of its assets. Analyzing the company's current market capitalization, an investor assesses the aggregate value of all shares as an indicator of the business's market scale, where breaking through price levels signals either an expansion of fundamental value or an increase in the risk of capital loss.

Key competitors